First Trust Advisors’s Theravance Biopharma TBPH Stock Holding History

First Trust Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$308K	Buy	18,959 +3,099	+20%	+$54.8K	﹤0.01%	2455
2025 Q4	$297K	Buy	+15,860	New	+$263K	﹤0.01%	2466
2021 Q2	–	Sell	-30,564	Closed	-$624K	–	2550
2021 Q1	$624K	Buy	+30,564	New	+$581K	﹤0.01%	2144
2020 Q4	–	Sell	-43,608	Closed	-$645K	–	2410
2020 Q3	$645K	Sell	43,608 -33,977	-44%	-$636K	﹤0.01%	1939
2020 Q2	$1.63M	Sell	77,585 -11,831	-13%	-$304K	﹤0.01%	1486
2020 Q1	$2.07M	Buy	89,416 +38,724	+76%	+$969K	﹤0.01%	1256
2019 Q4	$1.31M	Buy	+50,692	New	+$985K	﹤0.01%	1771
2019 Q2	–	Sell	-83,039	Closed	-$1.88M	–	2498
2019 Q1	$1.88M	Sell	83,039 -4,594	-5%	-$116K	﹤0.01%	1581
2018 Q4	$2.24M	Buy	+87,633	New	+$2.37M	0.01%	1407
2017 Q4	–	Sell	-21,118	Closed	-$723K	–	2458
2017 Q3	$723K	Buy	21,118 +8,700	+70%	+$284K	﹤0.01%	1961
2017 Q2	$495K	Sell	12,418 -2,880	-19%	-$111K	﹤0.01%	2064
2017 Q1	$563K	Sell	15,298 -24,457	-62%	-$781K	﹤0.01%	2041
2016 Q4	$1.27M	Buy	+39,755	New	+$1.23M	﹤0.01%	1721

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors's TBPH Position: Q1 2026 in Review

First Trust Advisors increased its Theravance Biopharma (TBPH) stake by 20% in Q1 2026, buying an estimated $54.8K and bringing the position to 18,959 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2455.

First Trust Advisors first reported a position in TBPH in Q4 2016 and has held it in 13 quarters since. The position peaked at $2.24M in Q4 2018. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

First Trust Advisors held 18,959 shares of Theravance Biopharma worth $308K as of Q1 2026.
First Trust Advisors bought 3,099 Theravance Biopharma shares in Q1 2026, an estimated $54.8K.
Theravance Biopharma made up ﹤0.01% of First Trust Advisors's portfolio in Q1 2026, its #2455 holding.
First Trust Advisors first reported a position in Theravance Biopharma in Q4 2016 and has held it in 13 quarters since.
First Trust Advisors's Theravance Biopharma position peaked at $2.24M in Q4 2018.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.